Brief Review on Combined Therapy of Sofosbuvir and Daclatasvir against Hepatitis C Virus | ||
| Zagazig Veterinary Journal | ||
| Volume 53, Issue 3, September 2025, Pages 219-230 PDF (398.81 K) | ||
| Document Type: Review Article | ||
| DOI: 10.21608/zvjz.2025.302500.1253 | ||
| Authors | ||
| Ahmed AH Ali; Mohamed El- Bakry; Fatma Abdallah; Attia A Abd Elrahman* | ||
| Department of Virology, Faculty of Veterinary Medicine, Zagazig University, 44511, Zagazig, Egypt. | ||
| Abstract | ||
| Hepatitis C virus is a hepatotrophic, enveloped positive sense RNA virus belonging to the Hepacivirus genus and family Flaviviridae. Hepatocellular carcinoma (HCC), liver cirrhosis, and severe liver diseases are associated with hepatitis C virus (HCV) infections all over the world. According to the world health organization's annual report, around 71 million people worldwide are distressed with the virus, and approximately 400,000 of them pass away every year. HCV infection can be early diagnosed using serological assays. However, the delayed diagnosis may result in chronic infection, liver cirrhosis, liver cancer and death. There is no effective vaccine against hepatitis C. Because of the genetic diversity and complexity of HCV, only few treatments have been shown to be effective against all genotypes of the virus. Here, we review the current anti-HCV therapeutics such as direct acting antivirals (DAA) and discuss their mechanisms of action and drawbacks particularly Sofosbuvir and daclatasvir. | ||
| Keywords | ||
| hepatitis C virus; hepatocellular carcinoma; direct acting antivirals; anti-HCV therapeutics | ||
|
Statistics Article View: 63 PDF Download: 33 |
||
